TrialMelanoma research2021

Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).

Stergios J Moschos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.